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Abstract
The vascular-stromal elements of lymph nodes can play important roles in regulating the activities of the lymphocytes
within. During model immune responses, the vascular-stromal compartment has been shown to undergo proliferative
expansion and functional alterations. The state of the vascular-stromal compartment and the potential importance of
this compartment in a spontaneous, chronic model of autoimmunity have not been well studied. Here, we characterize
the vascular expansion in MRL-lpr/lpr lymph nodes and attempt to ask whether inhibiting this expansion can interfere
with autoantibody generation. We show that characteristics of vascular expansion in enlarging MRL-lpr/lpr lymph nodes
resemble that of the VEGF-dependent expansion that occurs in wild-type mice after model immunization. Surprisingly,
treatment with SU5416, an inhibitor of VEGF and other receptor tyrosine kinases, did not have sustained effects in
inhibiting vascular growth, but attenuated the anti-dsDNA response and altered the phenotype of the double negative T
cells that are expanded in these mice. In examining for anatomic correlates of these immunologic changes, we found
that the double negative T cells are localized within ectopic follicles around a central B cell patch and that these T cell-
rich areas lack the T zone stromal protein ER-TR7 as well as other elements of a normal T zone microenvironment.
SU5416 treatment disrupted these follicles and normalized the association between T zone microenvironmental
elements and T cell-rich areas. Recent studies have shown a regulatory role for T zone stromal elements. Thus, our
findings of the association of anti-dsDNA responses, double negative T cell phenotype, and altered lymphocyte
microenvironment suggest the possibility that lymphocyte localization in ectopic follicles protects them from regulation
by T zone stromal elements and functions to maintain autoimmune responses. Potentially, altering the lymphocyte
microenvironment that is set up by the vascular-stromal compartment can be a means by which to control undesired
autoimmune responses.
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Introduction
Lymph nodes are sites of immune responses, and, within lymph
nodes, the activities of and interactions among immune cells are
supported and regulated by a highly plastic vascular-stromal
compartment that can expand and undergo phenotypic alterations
during immune responses. The mechanisms that regulate these
vascular-stromal changes and how they contribute to the
progression and regulation of the immune response are just
beginning to be better understood ([1–4], [5,6]). In lupus and
other autoimmune diseases, lymph nodes can undergo hypertro-
phy. Abnormal tissue architecture or immune cell localization in
lymphoid tissues from patients with or in mouse models of systemic
autoimmune diseases have been described [7–15], but alterations
and potential significance of the vascular-stromal compartment in
these settings are not yet well understood.
The anatomic compartmentalization of B cells to polarized
follicles at the cortex and T cells and dendritic cells to the ‘‘T
zone’’ in the paracortex within lymph nodes is in part is dictated
by the unique identity of fibroblastic reticular cells (FRCs) in each
compartment. Specialized FRCs within the follicles express B cell-
attracting CXCL13, while T zone FRCs express CCR7 ligands
that promote the localization of CCR7-expressing T cells and
dendritic cells to the T zone [1],[2],[3],[16],[17]. The FRCs of
each compartment are specialized in other ways as well, with T
zone FRCs capable of having a regulatory role and limiting T cell
proliferation or activation [6,18–23]. The T zone FRCs also
express the extracellular matrix constituents and ensheathe a
reticular network of collagen-rich fibrils [1], [2], [16]. One of the
matrix proteins expressed by the T zone FRCs is a protein
recognized by the antibody ER-TR7, which is also expressed
highly in the plasma cell-rich medulla, but notably normally is
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responses in wild-type mice, well-delineated ectopic follicles with
distinct B and T cells zones have been described to appear in the
medulla. ER-TR7 is expressed within the T cell areas, suggesting
that the association between ER-TR7 and T zone areas remains
intact in these immunization-induced ectopic follicles [27].
The blood vessels of lymph nodes bring in cells, nutrients, and
oxygen. The high endothelial venules (HEVs) are specialized
postcapillary venules that are the portals of entry for circulating
lymphocytes and are mostly found in the T zone and medulla
[28]. Upon acute immunization, HEVs and other portions of
the blood vessels undergo a proliferative expansion that is
dependent on vascular endothelial growth factor (VEGF) and
mediated initially by CD11c+ cells and then by B and T cells
together. The process is rapid, with the initial burst of
proliferation occurring 2 days after immunization and signifi-
cant expansion occurring by day 5 [29,30]. Thereafter, there is
a re-establishment of vascular quiescence, whereby the vascu-
lature may continue to expand if the stimulus is of a chronic
nature (such as antigen emulsified in CFA) but the rate of
proliferation is attenuated. Along with the downregulation of
proliferation is downregulation of VCAM-1 on HEV endothe-
lial cells and, corresponding to this phenotypic alteration, the
efficiency with which HEV allow lymphocytes to enter. This re-
establishment of vascular quiescence is mediated by late-
accumulating CD11c
hi presumed dendritic cells [31]. These
and other vascular alterations have been studied mainly in the
context of antigen/adjuvant and infection models [32–35].
Lymph node vascular growth and functional alterations in a
spontaneous chronic lupus model has not been characterized,
and the potential therapeutic value of inhibiting the growth and
other alterations to autoantibody production is unknown.
In this paper, we characterize the vascular expansion that
occurs with progressive lymph node enlargement in the MRL/lpr
model of lupus and attempt to inhibit the vascular growth to ask
about the subsequent effects on autoantibody generation. The
MRL/lpr model is characterized by massive lymph node
enlargement in part due to the accumulation of CD4-CD8-
B220+ syndecan+ (herein referred to as ‘‘double negative’’) T
cells [9,36,37]. Surprisingly, treatment with the receptor tyrosine
kinase inhibitor SU5416 that inhibits VEGF receptors as well as
other receptor tyrosine kinases did not have sustained effects on
inhibiting vascular growth and yet was able to attenuate the anti-
dsDNA response and downregulate syndecan on the double
negative T cells. We found that double negative T cells were
localized around a central B cell area within ectopic follicles and
that, unlike normal T cell-rich areas, the T cell area within these
follicles seemed to exclude ER-TR7 and other T zone
constituents. SU5416 treatment led to disruption of these follicles
and normalized the association between T cells and T zone
stromal and other constituents. Our results indicate an associa-
tion between unique alterations of the vascular-stromal compart-
ment and autoimmunity and suggest the possibility that
manipulating the association of lymphocytes with the vascular-
stromal compartment could be used to regulate undesired
autoimmune responses.
Materials and Methods
Ethics statement
The Institutional Animal Use and Care Committee of the
Hospital for Special Surgery specifically approved this study and
all animal procedures were performed in accordance with their
regulations.
Mice
MRL+/+ and MRL-lpr/lpr mice were either obtained from
The Jackson Laboratory (Bar Harbor, ME) or bred at HSS from
Jackson Laboratory breeders. For the initial characterization of the
vascular expansion and the 2 and 11.5 week SUGEN compound
treatments, the JAX 006825 strain was used. This strain of MRL-
lpr/lpr mice demonstrated an attenuated lymphoproliferative
phenotype and longer life spans than had been typical for their
MRL-lpr/lpr mice (see http://jaxmice.jax.org/strain/006825.
html). The experiments utilizing 4–5 weeks of SU5416 treatment
used JAX strain 000485, which were the rederived MRL-lpr/lpr
line that had the more severe phenotype typical of the original
MRL-lpr/lpr mice.
SUGEN compound treatment
MRL-lpr/lpr mice were injected intraperitoneally with 500 ug
per 50–100 ul of SU5416 or SU1498 (Sigma, St. Louis, MO) or
DMSO vehicle every other day for indicated time periods.
Flow cytometry analysis
For all of our flow cytometric analyses except analyses of plasma
cells, we prepared single cell suspensions by digesting with
collagenase type II (Worthington, Lakewood, NJ) and stained
cells as described previously [30]. For proliferation studies, mice
were given intraperitoneal injections of 2 mg of BrdU at 18 hours
and 1 hour prior to sacrifice and 0.8 mg/ml BrdU in the drinking
water in between injections as previously described [30,31]. For
analysis of plasma cells, single-cell suspensions were obtained by
mashing lymph nodes through a 70 mm filter and staining with
antibodies for flow cytometry. Cells were analyzed using a
FACSCanto (BD Biosciences) and CellQuest Pro (BD Biosciences)
software.
Immunohistochemistry
Lymph nodes were flash-frozen and 7-mm sections were cut on a
cryostat. Sections were dried for 1 h, fixed for 10 min in acetone
and immunohistochemical staining of fresh-frozen sections was
performed as described previously [30]. HRP or alkaline
phosphatase-conjugated secondary Abs were from Jackson Im-
munoResearch Laboratories.
Antibodies
All antibodies used were from BD Biosciences (San Jose, CA)
unless otherwise specified. Abs used were against CD45, CD31,
peripheral node addressin (PNAd), gp38 (BioLegend, San Diego,
CA, or Developmental Studies Hybridoma Bank, Iowa City, IA),
CD11c (HL3), B220, CD19, IgD, CD21/CD35, CD3, syndecan,
BrdU, ER-TR7 (BaChem, Bubendorf, Switzerland), and LYVE-1
(Angio-Proteomie Boston, MA). Biotinylated peanut agglutinin
(PNA) was from Vector Laboratories (Burlingame, CA).
VEGF measurements
For lymph node VEGF levels, popliteal lymph nodes were
solubilized in modified RIPA buffer and subjected to VEGF
measurement using a commercial kit (R&D Systems, DuoSet
mouse VEGF) as previously described [30].
Serum titer ELISA
Anti-dsDNA ELISA was as described [38]. Briefly, double-
stranded DNA was prepared using the S1 nuclease method. Plates
were pre-coated with poly-L-lysine and then dsDNA before
addition of serum samples. For total IgG titers, plates were blocked
with 1% BSA in PBS prior to addition of serum samples. Bound
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esearch) and chromogenic substrate 3,39,5,59-Tetramethylbenzi-
dine (Sigma-Aldrich, St. Louis, MO).
Anti-dsDNA ELISPOT
Plates were coated with poly-L-lysine and dsDNA as for ELISAs
before adding cells suspended in RPMI with 2% FCS (Invitrogen,
Carlsbad, CA) for 4 hours. The rest of the assay was carried out as
described [39], with detection of bound IgG/M by anti-mouse
IgG/M-biotin (Jackson ImmunoResearch), streptavidin-alkaline
phosphatase (Jackson ImmunoResearch), and chromogenic sub-
strate 5-bromo-4-chloro-3-indolyl-phosphate (Sigma). Spots per
well were counted and back-multiplied to total organ counts to
generate spots per organ.
Results
Enlarged MRL-lpr/lpr lymph nodes demonstrate vascular
expansion and state of re-established quiescence
To understand whether lymph node enlargement in lupus-
prone MRL-LPR/LPR/lpr mice was accompanied by vascular
growth and whether the characteristics of the vascular growth was
similar to that after immunization, we used flow cytometry to
examine endothelial cells over time, gating as we have done in
other studies [29–31,40] on CD45
negCD31
pos cells to delineate the
total endothelial cell population (‘‘Total EC’’). Within this
population, endothelial cells can be divided into peripheral node
addressin (PNAd)
pos and PNAd
neg cells. PNAd marks HEV
endothelial cells [28,41], and thus we refer to PNAd
pos endothelial
cells here as ‘‘HEV endothelial cells’’. PNAd
neg endothelial cells
represent a mixture of mostly blood endothelial cells and less
lymphatic endothelial cells (about a 60:40 mixture in brachial
lymph nodes in wild-type mice [29]) and are termed ‘‘non-HEV
mixed endothelial cells.’’ As lymph node cellularity (Fig. 1A) and
anti-dsDNA titers (Fig. 1B) increased in MRL-lpr/lpr mice over
time, endothelial cell numbers increased concomitantly (Fig. 1C).
Both HEV and non-HEV mixed endothelial cells expanded in
numbers over time (Fig. 1C).
We examined whether the increase in endothelial cell numbers
involved an increase in proliferation. Mice were pulsed with BrdU
for 18 hours and endothelial cell proliferation rate was determined
by the percentage of endothelial cells that were BrdU
pos.
Endothelial cell proliferation rates were modestly higher in
MRL-lpr/lpr lymph nodes, reflecting mainly higher proliferation
in the non-HEV mixed endothelial cell population (Fig. 1D).
However, because endothelial cell numbers were expanding in the
MRL-lpr/lpr mice, the number of proliferating endothelial cells
actually increased as lymph nodes became enlarged in these mice
(Fig. 1E). Lymph node vascular expansion in MRL-lpr/lpr mice,
then, was accompanied by an increase in the number of
proliferating endothelial cells, although the rate of proliferation
was only modestly increased over that of MRL+/+ mice. VEGF
levels were greater in the enlarged lymph nodes of MRL-lpr/lpr
mice (Fig. 1F), suggesting that, similar to lymph nodes stimulated
by model immunizations [30,40], VEGF might contribute to the
vascular proliferation and expansion.
Upon acute immunization, lymph node endothelial cells
undergo a period of re-established quiescence after the initial
proliferative burst and expansion [30,31]. We entertained the
possibility that we had missed any acute proliferative burst in
MRL-lpr/lpr nodes because we had examined over long time
intervals and that the slightly increased rate of endothelial cell
proliferation observed in the MRL-lpr/lpr lymph nodes reflected a
period of re-established vascular quiescence. We examined HEV
trafficking efficiency and found that 15-fold fewer naı ¨ve lympho-
cytes were able to enter lymph nodes per HEV endothelial cell in
MRL-lpr/lpr mice when compared to MRL-+/+ mice (Fig. 1G).
Together, the modestly increased rate of endothelial cell
proliferation and the reduced HEV trafficking efficiency were
consistent with the idea that the lymph node vasculature in MRL-
lpr/lpr mice at 2 and 4 months of age were in a period of re-
established vascular quiescence.
We have shown that different CD11c
pos populations play
distinct roles in regulating lymph node vascular growth and
quiescence after immunization [29,31]. CD11c
med cells play a
predominant role in the initiation of vascular growth while
CD11c
hi presumed dendritic cells are critical for the subsequent
re-establishment of vascular quiescence and stabilization [29,31].
At homeostasis, CD11c
hi cells are at low numbers relative to
CD11c
med cells. Both populations accumulate over the course of a
primary immune response, with CD11c
med cells initially outpacing
the CD11c
hi cells during the initiation of vascular expansion. With
the onset of vascular quiescence and stabilization, CD11c
hi cells
accumulate more rapidly and the ratio of CD11c
hi cell: CD11c
med
cell increases [31]. In the MRL-lpr/lpr nodes, lymphocytes,
including the double negative T cells, accounted for the majority
of the cells (Fig. 1H). However, both CD11c
hi and CD11c
med cells
also accumulated (Fig. 1I), and the ratios of CD11c
hi cell:
CD11c
med cell were increased at 2 and 4 months (Fig. 1I–J).
Together, these results suggest that the vasculature is continually
expanding while in a state of re-established quiescence in enlarging
MRL-lpr/lpr lymph nodes.
Treatment with VEGFR inhibitor SU5416 reduces anti-
dsDNA titers cells without long term effects on vascular
expansion
We wanted to ask whether inhibiting lymph node vascular
expansion could reduce the ensuing autoantibody generation. We
treated mice with SU5416, a small molecule receptor tyrosine
kinase inhibitor that inhibits VEGF receptors as well as having
activity against other receptor tyrosine kinases such as Flt-3 and
PDGFR-beta [42–46]. Treatment of 2 month-old MRL-lpr/lpr
mice for 2 weeks, when endothelial cell numbers and anti-dsDNA
titers were rising (Fig. 1B, 1C), resulted in reduced numbers of
HEV endothelial cells (Fig. 2A), suggesting that SU5416 had the
potential capacity to reduce vascular expansion, at least in the
short term.
We then treated mice with SU5416 for 11.5 weeks, starting at 2
months of age. To ask if any potential effects could be attributable
to the VEGF receptor-inhibiting activity of SU5416, we treated
other mice with SU1498, another inhibitor of VEGF receptor
tyrosine kinases that does not inhibit Flt-3 [44,47]. One mouse out
of 4 treated with SU5416 for each of 2 experiments died at 10–11
weeks of treatment. Urine protein of these mice was not any higher
than other mice in the group (data not shown) and these deaths
were potentially consistent with toxicity of SU5416 that has been
previously described [48]. Endothelial cells numbers were
unchanged by either SU5416 or SU1498 in brachial lymph nodes
(Fig. 2B), suggesting that compensatory mechanisms may have
overcome the prolonged VEGF receptor blockade or that VEGF
is not an important mediator of the prolonged vascular expansion
in MRL-lpr/lpr nodes. CD11c
hi presumed dendritic cells were
also not consistently reduced, suggesting potential compensation
for any SU5416-mediated Flt3 blockade (data not shown). Total
lymph node cellularity was also not consistently altered by SU5416
(data not shown). Remarkably, however, SU5416 attenuated the
rise in anti-dsDNA titers (Fig. 2C) with less effect on total serum
IgG (Fig. 2D).
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could reflect at least in part fewer anti-dsDNA-expressing plasma
cellsinlymphnodes,weexamineda separatecohortofMRL-lpr/lpr
mice that was treated with SU5416 for 5–6 weeks starting at 3
months of age. We enumerated plasma cells by flow cytometry,
gating onB220
losyndecan
posCD3
neg cells.Total plasmacellnumbers
were unchanged with SU5416 treatment in axillary nodes and
spleen (Fig. 2E), but anti-dsDNA-secreting cells as detected by
ELISPOT assay were reduced in number in lymph nodes (Fig. 2F).
Together,theseresultssuggestedthatSU5416treatmentreducedthe
number of anti-dsDNA-secreting plasma cells with a lesser effect on
disrupting the general plasma cell population.
The double negative T cells in MRL-lpr/lpr mice account for a
large portion of the cellularity in MRL-lpr/lpr lymph nodes over
time [36] (Fig. 1H) and may help promote autoantibody responses
[49]. The number of double negative T cells in lymph nodes was
not consistently affected by SU5416 (data not shown). These cells
express syndecan [37], and remarkably, syndecan levels on these
cells were downregulated in lymph nodes upon SU5416 treatment
(Fig. 2G). In comparison, double negative cells in spleen expressed
lower and more heterogenous levels of syndecan than in lymph
nodes (Fig. 2G), suggesting lymphoid tissue-specific regulation of
double negative T cell phenotype. Splenic double negative T cells
showed modest reduction of syndecan with SU5416 (Fig. 2G).
Although the function of syndecan on the double negative T cells
is unknown, the phenotypic change in the double negative T cells
suggested the possibility of a functional change with SU5416.
Double negative T cells are located in ectopic follicles
that lack normal T zone stromal and other elements and
SU5416 normalizes lymphocyte-microenvironment
relationship
We stained sections to ask whether anatomic alterations
accompanied the reduction in anti-dsDNA and double negative
Figure 1. MRL-lpr/lpr lymph node vasculature shows expansion and re-established quiescence with course of disease. MRL+/+ and
MRL-lpr/lpr mice were examined at indicated ages; brachial lymph nodes were used for flow cytometry-based studies (A, C–E, G–J) and popliteal lymph
nodes were used for VEGF determination (F). (A)Lymph node cellularity as determined by countof lymphnode cells.(B)Serum anti-dsDNAIgGtiters. (C)
Numberofendothelialcellsperlymphnodeasdeterminedbyflowcytometry.‘‘TotalEC’’=CD45
negCD31
poscells;totalendothelialcellsarecomprisedof
PNAd
pos ‘‘HEV EC’’ and PNAd
neg ‘‘nonHEV mixed EC.’’ (D) Endothelial cell proliferation rate as determined by the percent of endothelial cells that are
BrdU+. (E) Number of proliferating (BrdU+) endothelial cells per lymph node. (F) VEGF levels in lymph nodes. Each symbol represents 1 mouse. (G) HEV
trafficking efficiency. About 3610
7 CFSE-labeled splenocytes were intravenously injected into 3.5 month old mice at 30 minutes prior to sacrifice. HEV
trafficking efficiency was defined as the number of CFSE-labeled splenocytes that entered the lymph node divided by the number of HEV endothelial
cells. n=3 mice per condition. Representative of 3 similar experiments. (H) Number of lymphocyte subsets over time. Cells were identified as follows:
‘‘B220+ T cells’’ were B220
posCD3
pos cells; ‘‘B2202 T cells’’ were B220
negCD3
pos cells; ‘‘B cells’’ were B220
posCD3
neg cells. (I) Number of subsets of CD11c+
cells over time. (J) Ratio of CD11c
hi cells to CD11c
med cells over time. For A–E, H–J, n=6 mice per condition over 3 experiments. For A–J, *=p,.05 and
**=p,.01 in comparison to the same measurement in the age matched MRL+/+ mice using t-test.
doi:10.1371/journal.pone.0032828.g001
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MRL-+/+ mouse at day 8 after immunization with ovalbumin in
CFA (OVA/CFA) is shown for comparison purposes. In contrast
to the distinct B cell follicles and T zones in the stimulated MRL+/
+ node (Fig. 3Ai) and consistent with the observations of Lieberum
and Hartmann [8], MRL-lpr/lpr nodes were filled with well-
delineated ectopic follicles consisting of a central B cell zone and a
corona of T cells (Fig. 3Aii, 3Aiii). Consistent with the localization
of double negative T cells in the corona of the follicles [8], the
coronae were syndecan
med (Fig. 3Bii, 3Biii). Some of these follicles
contained PNA+ germinal centers within the central B zone
(Fig. 3Cii, 3Ciii). Some of the follicles were surrounded by ‘‘bare’’
CD19
negCD3
neg areas (Fig. 3Aii, 3Aiii double asterisks) containing
syndecan
hi plasma cells (Fig. 3Bii, 3Biii double asterisks) and
LYVE1+ lymphatic sinuses (Fig. 3Dii, 3Diii double asterisks). The
accumulation of plasma cells and lymphatic sinuses are hallmarks
of medullary cords (Fig. 3Bi and 3Di) and the delineation of the
ectopic follicles by plasma cell- and lymphatic-rich areas suggests
that many of the ectopic follicles are located within a greatly
engorged medulla.
Some of the follicles had a cortical location (3Aii, 3Aiii), similar
to that of normal B cell follicles (Fig. 3Ai), although these follicles
also had the abnormal corona of syndecan
med (double negative) T
cells (Fig. 3Bii, 3Biii). Furthermore, while cortical B cell follicles
are normally juxtaposed to (Fig. 3Ai) and can receive input from
the subcapsular sinus [50,51], a thick layer of syndecan+ T cells
appeared interposed between the cortical follicles and the
subcapsular sinus in the MRL-lpr/lpr nodes (Fig. 3Aii, 3Aiii,
3Bii, 3Biii).
Syndecan
neg T cells that normally inhabit the paracortex could be
observed in patches between some of the ectopic follicles (Fig. 3Aiii,
3Biii,asterisk).CD11c
posdendriticcellsare normallyconcentratedin
the T zone (Fig. 3Ei). In the MRL-lpr/lpr nodes, they were relatively
sparse in the zones occupied by syndecan
medCD3
pos Tc e l l sw i t h i n
the follicles, and appeared to more densely populate the areas
occupied by normal syndecan
negCD3
bright T cells (Fig. 3Eii, 3Eiii,
asterisks). Similarly, the large, thick-walled, CD31
hi HEVs are
mainly localized in the T zone and medulla in wild-type mice
(Fig. 3Bi, 3Ei, 3G, 3H), but tended to be relatively sparse within the
double negative T cell-rich corona of the ectopic follicles (Fig. 3Bii,
3Biii, 3Eii, 3Eiii, 3Fii, 3Fiii) as compared to the medullary (double
asterisk region in Fig. 3Biii, 3Eiii and 3Fiii)and T zone-like areas
surrounding the follicles (single asterisk region in Fig. 3Biii, 3Eiii and
3Fiii). The MRL-lpr/lpr lymph nodes, then, had the appearance of
medullary engorgement and were occupied mostly by ectopic
follicles full of double negative T cells and B cells. Normal
paracortical T cells and associated T zone elements appeared to
be squeezed into small areas between some of the ectopic follicles.
Figure 2. SU5416 reduces anti-dsDNA and alters T cell phenotype but without sustained effect on vascular growth. (A–D) MRL-lpr/lpr
mice (JAX 006825) were treated for either 2 weeks (A) or 11.5 weeks (B–D) with indicated treatments starting at 8 weeks of age. (E–G) MRL-lpr/lpr (JAX
000485) were treated for 5–6 weeks with SU5416 starting at 10 weeks of age. (A) Endothelial cell numbers in brachial lymph nodes after 2 weeks of
SU5416 treatment. n=3 mice per condition. (B) Endothelial cell numbers in brachial lymph nodes after 11.5 weeks of SU5416 treatment. n=4 DMSO
mice and 3 SU5416 mice. Representative of 2 similar experiments. (C) Anti-dsDNA titers and (D) total IgG titers in serum over time. For (C–D), ELISA for
serum from 0, 2, and 4 weeks was run independently from serum at 8, 10, and 11.5 weeks. n=4 mice per treatment except at 11.5 weeks, when n=3
for SU5416 (see text). Representative of 2 similar experiments. (E) Number of plasma cells per organ. n=4 mice per treatment over 3 experiments. (F)
Number of anti-dsDNA-secreting cells as determined by ELISPOT. n=4 mice per treatment over 3 experiments. (G) Syndecan levels on indicated T cell
populations from SU5416 or DMSO-treated mice. Representative of 4 mice over 3 experiments. For (A–F), *=p,.05 and *=p,.01 when SU5416
treatment compared to DMSO treatment using t-test.
doi:10.1371/journal.pone.0032828.g002
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32828Figure 3. Follicles of double negative T cells exclude T zone constituents and SU5416 normalizes the microenvironment. MRL-lpr-lpr
mice were treated with SU5416 or DMSO vehicle for 11.5 weeks starting at 8 weeks of age and lymph nodes were examined. For comparison to a
stimulated wild-type lymph node, 10 week old MRL+/+ mice were immunized with OVA/CFA and draining brachial lymph nodes were examined at
day 8. (Part i of A–F), nearby sections from a single day 8 MRL+/+ brachial lymph node were stained as indicated. (Part ii of A–F), nearby sections from
a single brachial lymph node from a DMSO-treated MRL-lpr/lpr mouse were stained as indicated. (Part iii of A–F), higher magnification of boxed area
in corresponding images in part ii. (Part iv of A–F), nearby sections from a single brachial lymph node from a SU5416 -treated MRL-lpr/lpr mouse were
stained as indicated. (Part v of A–F), higher magnification of boxed area in corresponding images in part iv. (G–H) Higher magnification of (G)
medullary and (H) T zone areas in (Fi). ‘‘F’’ denotes follicle. (I–J) Higher magnification of (I) medullary-like and (J) T zone-like areas in (Fiii). (K) Higher
magnification of normalized T zone area in (Fv). Scale bars represent 500 um.
doi:10.1371/journal.pone.0032828.g003
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after treatment with SU4516 (Fig. 3Aiv–v), but the medulla
appeared more centralized and less engorged, as indicated by the
more centrally located syndecan
hi plasma cells and LYVE1
staining (Fig. 3Biv, 3Div). The well-circumscribed ectopic follicles
filled with syndecan
medCD3
pos cells appeared smaller and fewer
and were mostly localized near or within the normalized medulla
(Fig. 3Aiv, 3Biv, 3Div). Consistent with the flow cytometry findings
(Fig. 2 G), CD3
pos T cells in the paracortex had appreciably
reduced levels of syndecan after SU5416 (Fig. 3Biv-2Bv), giving a
more normalized appearance to the paracortex. Additionally,
more even distribution of CD11c
pos cells and HEVs (Fig. 3Eiv–
3Ev) contributed to the impression of a normalized paracortex.
The syndecan
medCD3
pos cells that were detectable remained
localized to the outer boundaries of the cortical follicles after
SU5416 (Fig. 3Aiv, 3Biv–v). SU1498, in contrast, did not have
these effects on the lymph node anatomical organization (data not
shown). Together these results suggest that there is disruption of
ectopic follicles and normalization of the lymph node organization
in association with the reduction in anti-dsDNA and double
negative T cell phenotype changes after SU5416.
We examined the distribution of ER-TR7, a component of the
extracellular matrix secreted by FRCs [27], to better understand
the alterations in the lymph node architecture in the MRL-lpr/lpr
mice with and without SU5416 treatment. ER-TR7 staining is
normally quite bright and relatively disorganized in the medulla
(Fig. 3Fi, 3G) while it shows a distinct reticular pattern in the T
zone and (Fig. 3Fi, 3H). It is normally largely excluded from the B
cell follicles, defining the border between the T zone and the B cell
follicles [24–27] (see Fig. 3H). In the MRL-lpr/lpr nodes, bright
medullary-type ER-TR7 staining could be observed in the
medullary cord-like areas (Fig. 3Fiii double asterisks and Fig. 3I).
In the areas occupied by syndecan
negCD3
hi T cells (Fig. 3Aiii
asterisks, 3Biii asterisks), normal T zone reticular ER-TR7 staining
was seen (Fig. 3Fiii asterisks, 3J). Remarkably, despite the T cells
within the ectopic follicles (Fig. 3Aii–iii, 4B), only sparse ERTR7
staining was seen within the ectopic follicles (Fig. 3Fii–iii, 4E). ER-
TR7, then, appeared excluded from the zone of double negative T
cells within the ectopic follicles in MRL-lpr/lpr mice.
With SU5416 treatment, a more normal central pattern of
bright medullary ER-TR7 staining (Fig. 3Fiv) was consistent with
the idea of a normalized medullary compartment. In the
normalized paracortical T zone, areas occupied by T cells now
no longer lacked ER-TR7 (Fig. 3Aiv–v, 3Fiv–v, 4C, 4F). The
pattern of ER-TR7 in these T cell areas was reticular, resembling
that of a normal T zone (Fig. 3Fiv–v, 3K). Notably, ER-TR7
remained sparse in area just under the subcapsular sinus occupied
by the remaining syndecan
medCD3
pos T cells (Fig. 3Biv, 3Fiv).
These results together indicate that T zone microenvironmental
constituents including ER-TR7, HEVs, and dendritic cells are
relatively lacking in the T cell-rich areas of the ectopic follicles and
that SU5416-induced disruption of ectopic follicles is accompanied
by normalized association between T cells and T zone
microenvironmental constituents. These results suggest a potential
scenario whereby double negative T cells and the associated B cells
within the ectopic follicles are sequestered and protected from a
normal T zone microenvironment.
The relative lack of ER-TR7 staining within the ectopic follicles
is reminiscent of the ER-TR7 exclusion from normal B cell
follicles. In support of a B cell follicle-type microenvironment
within the ectopic follicles, these follicles contained a network of
CD21/CD35
hi cells (Fig. 4B, 4E, 4H) resembling follicular
dendritic cells (FDCs), the specialized stromal cells of the B cell
follicles (Fig. 4A, 4D, 4G). Upon SU5416 treatment, the patches
containing CD21/CD35
hi cells (FDCs) along with CD21/
CD35
med cells (B cells) could still be observed (Fig. 4C, 4F).
However, while ER-TR7 was excluded from the CD21/CD35+
zones even in instances where ER-TR7 was directly abutting the
CD21/CD35+ zones in control MRL-lpr/lpr mice (Fig. 4H),
SU5416 treatment led to the appearance of reticular ER-TR7
staining within the CD21/CD35+ patches. The ER-TR7 staining
within the CD21/CD35+ zone appeared continguous with the
ER-TR7 staining at the border of the zones, giving the appearance
of an invasive process (Fig. 4I, 4J). Interestingly, Cyster and
colleagues recently showed that ablation of FDCs resulted in
invasion of ER-TR7 and other T zone constituents into the areas
formerly occupied by B cell follicles [26], suggesting the possibility
that SU5416 could have disrupted ectopic follicles by initially
affecting FDC integrity. Together, our results suggested that the
ectopic follicles containing double negative T cells and B cells in
MRL-lpr/lpr mice are in a microenvironment that at least in part
resembles that of B cell follicles, and that disruption of the ectopic
follicles exposes both T and B cells of the follicles to a T zone-type
microenvironment.
Discussion
Our results showed that lymph node hypertrophy in the MRL-
lpr/lpr model of lupus is accompanied by vascular expansion and
also revealed that double negative T cells and B cells are organized
within ectopic follicles that were disrupted in association with
SU5416-induced attenuation of the anti-dsDNA response. The T
cell-rich corona of the ectopic follicles lacked a normal T zone
microenvironment, and SU5416-induced follicular disruption
normalized the T cell-microenvironment association. The associ-
ation of the microenvironmental alterations with anti-dsDNA
responses and double negative T cell phenotype alterations raises
the possibility that these phenomena are related and that
microenviromental alterations might contribute to regulating
autoimmune responses. T zone FRCs have been shown to have
a regulatory capacity [18–23], suggesting the possible scenario that
sequestration of lymphocytes in ectopic follicles maintains
autoimmune responses at least in part by protecting them from
regulation by T zone FRCs. Such a scenario would also suggest
that targeting the relationship between the lymphocytes and the
microenvironment may be a means by which to inhibit
autoimmune responses.
Our results showed that the characteristics of vascular
expansion accompanying the progressive lymph node enlargement
in MRL-lpr/lpr mice are similar to the vascular expansion that
occurs after model immunizations. By examining at long intervals
in the MRL-lpr/lpr mice, we were likely to have missed any
proliferative burst that characterizes the first days after acute
immunization of wild-type mice [29,30]. However, the modestly
elevated endothelial cell proliferation rate, the reduced HEV
trafficking efficiency, and the moderately elevated VEGF all were
consistent with the idea that the blood vessels were in the state of
re-established quiescence that follows the initial burst of prolifer-
ative expansion [31]. The increased ratio of CD11c
hi
cell:CD11c
med cell further supports this idea and also raises the
possibility that, similar to lymph nodes after model immunization,
CD11c
hi cells may also regulate this phase of quiescence in MRL-
lpr/lpr nodes. Short term VEGF receptor blockade with SU5416
reduced HEV numbers, suggesting that, similar to lymph nodes
after model immunization [30,40], the elevated VEGF levels
contributed to the vascular expansion. The ineffectiveness of long
term blockade, though disappointing in not allowing us to
understand the importance of vascular expansion to the
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VEGF blockade that we had previously observed for homeostatic
HEV proliferation [40]. The similarity in vascular alterations and
potential regulatory mechanisms suggest that the vasculature
undergoes a somewhat stereotypical response upon lymph node
stimulation and that mechanisms gleaned from studying vascular
regulation after model immunization can be useful for under-
standing lymph node vascular regulation in spontaneous chronic
autoimmune models. It will be interesting in the future to
understand whether there are characteristics of the vasculature
or regulatory mechanisms that are specific for promoting or
limiting autoimmune responses.
Our results suggest the possibility that localization of double
negative T cells with B cells in ectopic follicles is related to the
maintenance of the anti-dsDNA response. Whether and how they
are related remains to be fully elucidated, but double negative T
cells from lupus patients can help B cells to generate an anti-
dsDNA response [52–54], and these cells in MRL-lpr/lpr mice
express IL-17 and can contribute to pathogenic humoral responses
[49]. These features in addition to their compartmentalization
with B cells raise the interesting possibility that they resemble a
type of follicular T helper cell that can potentially contribute to
pathology by helping to promote anti-dsDNA and other
autoantibody responses. SU5416 induced the reduction of
syndecan on the double negative cells, and it would be interesting
to understand whether the level of syndecan is related to their
ability to generate IL-17 and/or contribute to humoral responses.
While we do not currently understand whether lymphocyte
function or the regulation of the ectopic follicle compartmental-
ization was more directly affected by SU5416, the SU5416
treatment resulted in exposure of the double negative T cells and
associated B cells to a more T zone-like microenvironment that
included ER-TR7 and a greater complement of HEVs and
dendritic cells. Recent studies have shown that T zone FRCs can
play a regulatory role in limiting T cell activation and proliferation
by a variety of mechanisms [18–23]. Thus, an attractive potential
Figure 4. SU5416 induces infiltration of ER-TR7 into the B cell areas within ectopic follicles. MRL-lpr-lpr mice were treated with SU5416 or
DMSO vehicle for 11.5 weeks starting at 8 weeks of age and lymph nodes were examined. For comparison to a stimulated wild-type lymph node, 10
week old MRL+/+ mice were immunized with OVA/CFA and draining brachial lymph nodes were examined at day 8. (A, D) nearby sections from a
single brachial lymph node from a DMSO-treated MRL-lpr/lpr mouse were stained as indicated. (B, E) Nearby sections from a single axillary lymph
node from a DMSO-treated MRL-lpr/lpr mouse were stained as indicated. (C,F) Nearby sections from a single axillary lymph node from a SU5416-
treated MRL-lpr/lpr mouse were stained as indicated. (G) Higher magnification of B cell follicle border indicated in (D, arrow). (H) Higher magnification
of ectopic follicle border indicated in (E, arrow). (I, J) Higher magnification of border of B cell areas indicated in (F). (I) is magnification of area denoted
by single arrow and (J) is magnification of area denoted by double arrows. Scale bars represent 500 um.
doi:10.1371/journal.pone.0032828.g004
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reduced anti-dsDNA at least in part by exposing the double
negative T cells and accompanying B cells within the follicles to
the regulatory influence of T zone FRCs.
The targets of the SU5416 that are involved in the reduction in
anti-dsDNA responses and in lymph node alterations are currently
unclear. The lack of effect of SU1498 on these parameters would
suggest that VEGF receptor inhibition is not involved. SU5416
also inhibits Flt3, which is important for dendritic cell develop-
ment [44,45,55]. CD11c
hi presumed dendritic cells were not
reduced in number with long term SU5416 treatment, but
whether SU5416-mediated blockade affected dendritic cell
function was not assessed. Dendritic cells are important for the
generation of autoantibodies in MRL-lpr/lpr mice [56] and we
and others have shown that CD11c+ dendritic and other cells can
regulate FRC proliferation and function, and potentially in a
direct manner [21,29,31]; it is possible that SU5416 induced
alterations in dendritic cell function that normalized the stromal
compartment and reduced anti-dsDNA responses. Similarly,
blockade of receptor tyrosine kinases such as CSF-1R, c-kit, or
c-ret by SU5416 [43,57,58]could also have affected other cells
involved in regulating the stromal elements and the anti-dsDNA
response. SU5416 also has activity against PDGFR-beta [59],
which is expressed by FRCs [60], and could potentially modulate
their function. Treatment with imatinib, an inhibitor of PDGF
receptor and c-kit receptor kinases, reduced lymph node size and
ameliorated nephritis in MRL-lpr/lpr mice [61], and it would be
interesting to understand whether imatinib has the same effects as
SU5416 on anti-dsDNA responses and lymph node organization.
Identifying the critical SU5416 targets that are important for
the effects in the MRL-lpr/lpr lymph nodes may have implications
for potential new therapies in lupus. SU5416 was tested in clinical
trials for its anti-angiogenic and anti-tumor properties and was
discontinued as a clinical agent because of side effects and
suboptimal pharmacokinetics. Sunitinib is a subsequent generation
VEGF receptor inhibitor that has a similar profile of activity
against multiple receptor tyrosine kinases and that is orally
available. It is in clinical use as a first line agent in patients with
metastatic clear cell renal cell carcinoma [59,62], suggesting the
possibility of relatively quick translation from pre-clinical results
into clinical practice for lupus and other systemic autoimmune
diseases. However, anti-VEGF activity may not be desirable in
lupus, as the renal vasculature is dependent on podocyte-expressed
VEGF [63] and NZB/WF1 mice treated with antibodies to
VEGFR2 had accelerated nephropathy [64]. SU5416 induced
only slightly more proteinuria in the MRL-lpr/lpr mice that we
examined at 11.5 weeks of treatment (30+ to 100+ in SU5416-
treated mice as compared to ,30 to 30+ in DMSO-treated mice;
data not shown), but more specific agents that do not compromise
renal function would seem to be more desirable.
Our results provide new insight into the features of the immune
system that are associated with autoantibody generation. Although
more work will be needed to fully establish the relationship
between autoantibody generation and lymph node microenviron-
mental alterations, these associations raise the possibility that
physical sequestration of autoimmune cells from regulatory
microenvironmental elements could potentially be a mechanism
for sustaining pathogenic responses and that targeting the
association of lymphocytes with the microenvironment may be a
strategy by which to control autoimmune responses. Testing this
model and understanding the generalizability of our findings in
other autoimmune models will be helpful to better understand the
potential utility of this strategy and also to provide further insight
into mechanisms of disease.
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